Samsung Biologics Launches CHF 1.46B Tender Offer for PolyPeptide
Event summary
- Samsung Biologics' Swiss subsidiary Samsung Peptide AG offers CHF 44.31 per PolyPeptide share, valuing the target at CHF 1.46B.
- The 40% premium over PolyPeptide's unaffected share price is backed by its largest shareholder, Draupnir Holding B.V., which owns 55.65% of shares.
- Tender offer period runs from September 15 to October 12, 2026, requiring 66⅔% acceptance threshold for completion.
- PolyPeptide's board unanimously recommends shareholders accept the offer, supported by an independent fairness opinion from IFBC AG.
The big picture
This acquisition positions Samsung Biologics to expand its contract manufacturing capabilities in peptide-based therapeutics, a growing segment in biopharmaceuticals. The deal reflects broader industry consolidation trends as CDMOs seek to enhance service offerings and scale production capacities. With PolyPeptide's global network of GMP-certified facilities, Samsung Biologics aims to strengthen its position in the competitive CDMO market, particularly in metabolic disease therapies like GLP-1.
What we're watching
- Regulatory Approval
- Whether Samsung Biologics secures all necessary approvals to complete the acquisition by year-end 2026.
- Shareholder Acceptance
- The pace at which minority shareholders tender their shares, given the 66⅔% threshold requirement.
- Integration Strategy
- How Samsung Biologics plans to integrate PolyPeptide's peptide manufacturing capabilities with its existing CDMO operations.
Related topics